PMC9315267_01
Schematic representation of the steps taken for biomarker selection in MIRIADE. CSF, cerebrospinal fluid.
fneur-13-890638-g0002.jpg
PMC9315267_01_fneur-13-890638-g0002.jpg
F2
Furthermore, ESRs developing novel biomarkers for the same type of dementia collaborated to share their selection criteria and compared selected biomarkers that would be pursued using alternative assay development techniques (antibody-based and mass spectrometry) (see the summary of the steps in Figure 2).